At the first surveillance visit after cancer surgery, attention naturally goes to the scans and the tumor markers. But for people who also had part of the pancreas removed, one number in the corner of the lab sheet often lingers after the imaging comes back reassuring: hemoglobin A1c (HbA1c). If it was normal before surgery and now sits in the 7 percent range, that is often less a sign of neglect than an expected consequence of living with less pancreas.
The pancreas does two jobs at once. Its exocrine function sends digestive enzymes into the intestine to break down food; its endocrine function releases hormones into the blood that regulate glucose. The more tissue is removed, the more both functions decline together. That is why diabetes appearing after pancreatic surgery does not sit comfortably in the same category as ordinary type 2 diabetes. Clinically it is named separately: type 3c diabetes, or pancreatogenic diabetes.
The most important difference is that the system for raising blood sugar weakens too. The pancreas makes not only insulin but also glucagon, the hormone that pulls glucose back up when it falls. When both are in short supply, glucose swings in both directions more easily. It can climb quickly after meals, drop further than expected if a dose runs strong or a meal is skipped, and recover more slowly on its own. The same HbA1c of 7.4 may mean a steady, modestly elevated level in one person and a pattern of alternating highs and lows in another.
For that reason it is safer not to set a target number alone. The wish to return to a pre-surgery value is entirely understandable, but in a body prone to hypoglycemia, an aggressively low target can add risk rather than remove it. A more useful question in clinic is not "how far down should this go" but "what range can I reach without low blood sugar episodes." It also helps to remember that HbA1c reflects an average over roughly the past two to three months, so anemia, chemotherapy, or a recent transfusion can pull it away from what daily readings actually show. Home glucose logs or continuous glucose monitoring (CGM) data make the picture far easier to interpret.
Digestion is missed almost as often as glucose. When enzyme output is low, fat passes through unabsorbed: stools may float or look oily, odor becomes stronger, the abdomen feels gassy and distended, and weight drifts down. Absorption becomes erratic, which in turn makes post-meal glucose harder to predict. If pancreatic enzyme replacement therapy (PERT) has been prescribed, it is reasonable to review whether the timing and dose still fit, and whether fat-soluble vitamins (A, D, E, K) and bone health should be checked as well. These adjustments belong with the prescribing team rather than being made independently.
Meal planning may also differ from standard diabetes advice. Losing weight to reduce insulin resistance is often presented as the default, but during recovery from cancer treatment, in a body that has already lost weight, muscle tends to go along with fat. Protecting protein and total calories, spreading carbohydrate across the day instead of concentrating it in one sitting, and adding sustainable activity such as walking often fit better. How much to change, and what to change, is worth deciding with a dietitian or the treating team.
It is worth learning the signs of low blood sugar in advance: trembling hands, cold sweat, sudden hunger, palpitations, dizziness, and slowed speech. Anyone taking glucose-lowering medication or insulin should be shown how to take about 15 grams of fast-acting carbohydrate and recheck after 15 minutes, and should note any night when a low is suspected so it can be shown at the next visit. People who drive or spend long stretches alone should raise this specifically.
When care is split across departments, glucose can quietly become no one's item. Deciding explicitly who owns it — cancer surveillance with the surgical or oncology team, glucose with endocrinology or primary care — lets blood sugar management find a place inside the recurring scan schedule. Bringing a single page to each visit helps: two to four weeks of fasting and post-meal readings, a current list of medications and enzyme capsules, weight trend, and the dates of any low-sugar episodes.
Some situations warrant contacting the team rather than waiting for the next appointment: repeated lows or a low that does not resolve on its own, a clear increase in thirst and urination with rapid weight loss, vomiting that prevents keeping meals or medication down, or fever and severe abdominal pain.
This article is general information and does not replace individual medical care. Target values, medication adjustments, and meal plans vary from person to person, so please discuss them with your own healthcare team.